drugset
Drugs / MVA-209-FSP
last change 3 days ago re-read 3 minutes ago

MVA-209-FSP

also known as Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP · Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP · MVA-209-FSPs

Vaccine

Developed for
cancer · colorectal carcinoma
Investigated by
Merck Sharp & Dohme LLC · National Cancer Institute (NCI) · Nouscom SRL

Trials 2

today NCT05078866 · Ph 1/2 NCT04041310 · Ph 1/2
20202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05078866 Nov 2022 → Apr 2025 overdue Lynch syndrome, colorectal carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1/2 NCT04041310 Oct 2019 → Oct 2026 expected cancer Nouscom SRL Active not recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MVA-209-FSP ClinicalTrials.gov intervention name — accepted as the source's own label NCT04041310 ↗
1

NCT05078866 ↗
Known as Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP “Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP” NCT05078866 ↗
Known as Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP “Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP” NCT05078866 ↗
Known as MVA-209-FSPs “MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP (MVA-209-FSPs) (1 boost)” NCT05078866 ↗
Modality Vaccine “MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP” NCT05078866 ↗
Route Intramuscular “Both Frame Shift Peptide (FSP) neoantigen-encoding genetic vaccines are administered intramuscularly” NCT04041310 ↗